Disease:
Nausea

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1062613 -24T>C, 113846006T>C, 17408422T>C, 210T>C, 5210T>C, HTR3A:C178T, Pro16Ser
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs10789970 -1710C>T, 113773946C>T, 17336362C>T, 3358C>T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs11030918 -756T>C, 243555T>C, 4055487T>C, 4115487T>C, 4564T>C
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs11214763 -761G>A, 113774895G>A, 17337311G>A, 4307G>A
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs1176713 113860425A>G, 1332A>G, 1395A>G, 1467A>G, 1491A>G, 17422841A>G, 19629A>G, Leu444=, Leu465=, Leu497=
A > G
Not Available
Leu444Leu
No VIP available No Clinical Annotations available VA
rs1176722 113848474G>A, 17410890G>A, 23-19G>A, 319-19G>A, 7678G>A, 86-19G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs1176744 113803028A>C, 17365444A>C, 32440A>C, 386A>C, Tyr129Ser
A > C
Missense
Tyr129Ser
No VIP available No Clinical Annotations available VA
rs1176746 113802601A>G, 17365017A>G, 32013A>G, 368+12A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs12806698 -269C>A, 244042C>A, 4055974C>A, 4115974C>A, 5051C>A
C > A
5' UTR
No VIP available No Clinical Annotations available VA
rs1799971 -11+28644A>G, 118A>G, 154360797A>G, 34162A>G, 397A>G, 47+29103A>G, 58530254A>G, Asn133Asp, Asn40Asp, OPRM1: A118G
A > G
Missense
Asn40Asp
No VIP available No Clinical Annotations available VA
rs2072660 *313T>C, 13465T>C, 154548721T>C, 6037363T>C
T > C
3' UTR
No VIP available No Clinical Annotations available VA
rs2072661 *472G>A, 13624G>A, 154548880G>A, 6037522G>A
G > A
3' UTR
No VIP available No Clinical Annotations available VA
rs2072671 20915701A>C, 7595789A>C, 79A>C, CDA: c.79A>C, CDA:79A>C, K27Q, Lys27Gln, p.Lys27Gln
A > C
Missense
Lys27Gln
No VIP available No Clinical Annotations available VA
rs2269577 -245C>G, 29196757G>C, 4804C>G, 8587326G>C
G > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs2276305 113803104G>A, 113803104G>C, 17365520G>A, 17365520G>C, 32516G>A, 32516G>C, 462G>A, 462G>C, Ala154=
G > A
G > C
Synonymous
Ala154Ala
No VIP available No Clinical Annotations available VA
rs2276307 113803887A>G, 17366303A>G, 33299A>G, 696+72A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs2302764 *68T>C, 16705T>C, 6963484T>C, 7360110T>C
T > C
3' UTR
No VIP available No Clinical Annotations available VA
rs3758987 -381T>C, 113775275T>C, 17337691T>C, 4687T>C
T > C
5' Flanking
No VIP available CA No Variant Annotations available
rs3892097 21915516C>T, 353-1G>A, 42524947C>T, 506-1G>A, 6937G>A, CYP2D6*4, CYP2D6:1846G>A, part of CYP2D6*4
C > T
Acceptor
No VIP available No Clinical Annotations available VA
rs4292956 *538C>T, 13690C>T, 154548946C>T, 6037588C>T
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs4532 -48G>A, 174870150C>T, 19681423C>T, 6014G>A
C > T
5' UTR
No VIP available CA No Variant Annotations available
rs5030655 -1098delA, -1563delA, -951delA, -988delA, 23419520delA, 277delT, 353-140delT, 40+3506delA, 42129084delA, 454delT, 51411delA, 51425delA, 5908delT, CYP2D6*6, CYP2D6:1707 del T, Trp152Glyfs, Trp93Glyfs, part of CYP2D6*6
A > -
Not Available
Trp152Gly
No VIP available No Clinical Annotations available VA
rs57098334 GGGTGGGCT, SLC6A4:
C > (CCCACCCGA)12
C > (CCCACCCGA)9
C > (CCCACCCGA)10
Not Available
No VIP available No Clinical Annotations available VA
rs6313 102C>T, 160+869C>T, 28449940G>A, 47469940G>A, 6230C>T, HTR2A:102C>T, HTR2A:T102C, Ser34=
G > A
Intronic
Ser34Ser
No VIP available No Clinical Annotations available VA
rs8175347 233760235_233760236TA[5][6][7][8], 5-TA insertion in promoter, 7-TA insertion in promoter, 8-TA insertion in promoter, UGT1A1*28, UGT1A1*36, UGT1A1*37, microsatellite, short tandem repeat
(TA)6 > (TA)8
(TA)6 > (TA)5
(TA)6 > (TA)7
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names: 
Synonym
Nauseated; Nauseous; Observation of nausea
PharmGKB Accession Id: PA445048
External Vocabularies

Curated Information ?

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Platinum compounds

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Induces
No related diseases are available

Publications related to Nausea: 27

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Salgia Ravi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology. 2013. Levy Florence, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands). 2013. Peng J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenetics and genomics. 2012. Er¿ulj Nina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2011. King David P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. The pharmacogenomics journal. 2011. Swan G E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British journal of cancer. 2011. Khan O A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants. Annals of the rheumatic diseases. 2010. Kim Eunjin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clinical pharmacology and therapeutics. 2010. Ravva P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Gianni Luca, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evolving novel anti-HER2 strategies. The lancet oncology. 2009. Jones Kellie L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and genomics. 2009. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer chemotherapy and pharmacology. 2009. Fujita Ken-Ichi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Naturally occurring variants in the HTR3B gene significantly alter properties of human heteromeric 5-hydroxytryptamine-3A/B receptors. Pharmacogenetics and genomics. 2008. Walstab Jutta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 2008. Ward Michael B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics. 2008. Niesler Beate, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene. Pharmacogenetics and genomics. 2008. Meineke Cornelia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2008. Tanaka Misuzu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. Herbst Roy S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. The American journal of tropical medicine and hygiene. 2006. Hill David R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. International journal of geriatric psychiatry. 2006. Whyte Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Journal of clinical pharmacy and therapeutics. 2006. Shams M E E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. The pharmacogenomics journal. 2006. Sugai T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. British journal of cancer. 2004. Marcuello E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics. 2004. Kaiser Rolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003. Tremblay Pierre-Benoit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002. Takahashi Hitoshi, et al. PubMed